DB
MBRX icon

Danske Bank’s Moleculin Biotech MBRX Stock Holding History

Danske Bank’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Hold
2
– – ﹤0.01% 1086
2026
Q1 		$5 Hold
2
– – ﹤0.01% 1107
2025
Q4 		$7 Buy
+2
New +$19 ﹤0.01% 1492
2024
Q4 		– Hold
0
– -$6 – 1548
2024
Q3 		– Hold
0
– – – 1546

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Danske Bank's MBRX Position: Q2 2026 in Review

Danske Bank held its Moleculin Biotech (MBRX) position steady in Q2 2026 at 2 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

Danske Bank first reported a position in MBRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $7 in Q4 2025. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Danske Bank held 2 shares of Moleculin Biotech worth $6 as of Q2 2026.
  • Danske Bank left its Moleculin Biotech share count unchanged in Q2 2026.
  • Moleculin Biotech made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1086 holding.
  • Danske Bank first reported a position in Moleculin Biotech in Q4 2025 and has held it in 3 quarters since.
  • Danske Bank's Moleculin Biotech position peaked at $7 in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.